Clinical trial · no report yet · Phase 2
NeoCOAST-2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05061550 ↗
- Recruiting
- AstraZeneca
- 67 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 46 | |
| YouTube | 11 | |
| Podcasts | 10 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Durvalumab; Oleclumab; Monalizumab; Dato-DXd; AZD0171; Carboplatin; Cisplatin; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin; Carboplatin/Paclitaxel; Volrustomig; Rilvegostomig
- Arms
- Arm 1: Oleclumab + Durvalumab + Platinum doublet chemotherapy (CTX) · Experimental
- Arm 2: Monalizumab + Durvalumab + CTX · Experimental
- Arm 3: Volrustomig (Dose Exploration) + CTX · Experimental
- Arm 4: Dato-DXd + durvalumab + single agent platinum · Experimental
- Arm 5: AZD0171 + durvalumab + CTX · Experimental
- Arm 6: Rilvegostomig + CTX · Experimental
- Arm 7: Dato-DXd + Rilvegostomig + single agent platinum · Experimental
- Enrollment
- 630 (estimated)
- Primary outcomes
- Number of participants with pathological complete response (pCR)
- Number of participants with adverse events (AEs) and serious adverse events (SAEs)
- Sponsor
- AstraZeneca with Parexel
- Start
- Apr 14, 2022
- Primary completion
- May 28, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05061550 · updated Sep 23, 2026
Publications
linked from the registry- Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L, Egenod T, Corre R, Kim DW, Garcia Campelo MR, Provencio Pulla M, Shim BY, Metro G, Bennouna J, Bielska AA, Yohannes AR, He Y, Dowson A, Kar G, McGrath L, Kumar R, Grenga I, Spicer J, Forde PM. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med. 2025 Aug;31(8):2788-2796. doi: 10.1038/s41591-025-03746-z. Epub 2025 May 31. PubMed 40450142